LUNIT INC Mediaroom - PR Newswire APAC

Lunit AI Predicts Breast Cancer Risk Up to 6 Years in Advance

* Two new studies show Lunit INSIGHT MMG cuts radiologist workload by 50% in a double reading env...

2024-10-23 21:00 1712

Lunit AI Predicts Breast Cancer Risk Up to 6 Years in Advance

Lunit to Present AI-Analyzed Immune Phenotype Study as Immunotherapy Response Predictor for Advanced Gastric Cancer at ESMO Congress 2024

* Lunit SCOPE IO® demonstrates potential to assess immune phenotype as an AI-powered biomarker fo...

2024-09-10 21:00 1414

Lunit to Present AI-Analyzed Immune Phenotype Study as Immunotherapy Response Predictor for Advanced Gastric Cancer at ESMO Congress 2024

Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing

* Lunit's AI-powered biomarker, Lunit SCOPE PD-L1 TPS, integrates into Roche's navify® Digital Pa...

2024-09-09 21:00 1313

Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker Testing

Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR

* AI-based tumor microenvironment classification utilizing Lunit SCOPE IO® shows promise for guid...

2024-09-03 21:00 1445

Immune Phenotyping Identified as Promising Predictive Biomarker by Lunit AI in Biliary Tract Cancer - New publication in CCR

Lunit's AI for Tuberculosis Detection Tops in 12-Product Comparative Study

* Lancet Digital Health study highlights Lunit INSIGHT CXR as top performer in TB screening, show...

2024-08-06 21:00 1831

Lunit's AI for Tuberculosis Detection Tops in 12-Product Comparative Study

Lunit's AI Solution Enhances Qatar's National Breast Cancer Screening Program

* Middle East's first full-scale AI adoption for national screening marks Lunit's latest mileston...

2024-07-22 21:00 2242

Lunit's AI Solution Enhances Qatar's National Breast Cancer Screening Program

Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

- Lunit's ASCO 2024 presentations to highlight advances including HER2 ultra-low detection and AI-p...

2024-05-24 22:07 5464

Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response

Lunit Completes Acquisition of Volpara: Pioneering Next-Level of AI-Driven Cancer Care

SEOUL, South Korea, May 22, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-po...

2024-05-22 21:00 2054

Lunit Completes Acquisition of Volpara: Pioneering Next-Level of AI-Driven Cancer Care

Lunit Achieves Historic Milestone: 100 Peer-Reviewed Papers Published on Its AI Medical Imaging Suite

- From research to real-world impact: Lunit demonstrates Lunit INSIGHT's clinical safety, effective...

2024-05-20 21:00 1995

Lunit Achieves Historic Milestone: 100 Peer-Reviewed Papers Published on Its AI Medical Imaging Suite

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

- Employing Lunit INSIGHT MMG, a Turkish study showcases 70% efficiency improvements, advancements ...

2024-04-08 21:00 1821

Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

- Lunit's AACR 2024 presentations to spotlight HER2 mutation insights and CNTN4's role in immunothe...

2024-04-01 21:00 1983

Lunit to Showcase 7 Studies at AACR 2024: Unveiling AI Innovations in HER2 Expression-Mutation Analysis and CNTN4 Biomarker Identification

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

- New research published in Clinical Cancer Research shows significant improvement in distant recur...

2024-03-26 21:00 1220

Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patients

Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal

* New supply contract to bring Lunit INSIGHT CXR to TeleDiag in France and Lunit INSIGHT MMG to t...

2024-03-18 21:00 1827

Lunit Expands Presence in Europe: to Deliver AI-powered Cancer Screening Solution to France and Portugal

Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment - New Study in Breast Cancer Research

- Lunit SCOPE HER2 and Lunit SCOPE ER/PR significantly improve pathologist concordance and accuracy...

2024-03-14 21:00 1885

Lunit SCOPE AI Enhances Pathologist Concordance and Accuracy in HER2, ER, and PR Assessment - New Study in Breast Cancer Research

Update on Lunit's Acquisition of Volpara: New Zealand High Court Initial Approval Secured

- Volpara shareholder meeting to be held on April 12, 2024: Culminating the acquisition journey for...

2024-03-13 21:00 1750

Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings

- Lunit to unveil four oral presentations and three poster presentations at ECR 2024, highlighting ...

2024-02-28 22:03 1378

Lunit Presents Seven Study Results at ECR 2024: Showcasing AI's Robust Performance in Diverse Clinical Settings

New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC

- A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-po...

2024-02-16 22:03 4974

Latest News